Regeneron Pharmaceuticals Newsroom

Express News | US FDA: Revoked Emergency Use Authorization for Regeneron's Regen-Cov as of Dec 13 - Website

Breakings01:12

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

BenzingaDec 23 22:00

SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?

Seeking AlphaDec 23 05:12

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

BenzingaDec 23 03:51

CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,152

Futu NewsDec 21 02:31 · Ratings

Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200

Futu NewsDec 21 02:31 · Ratings

TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230

Futu NewsDec 21 02:31 · Ratings

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,190, Keeps Outperform Rating

MT NewswiresDec 20 23:24 · Ratings

Regeneron Reports Positive Results for Two Anti-coagulant Drugs

Seeking AlphaDec 20 02:16

Express News | Regeneron Pharmaceuticals Inc - Regn7508 and Regn9933 Evaluated for Thrombosis Control

BreakingsDec 19 20:00

Regeneron to Advance Two Factor XI Antibodies Into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results

Regeneron PharmaceuticalsDec 19 13:00

REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study

Zacks Dec 18 22:35

Regeneron Pharmaceuticals Shares Are Trading Higher After the Company Announced Its QUASAR Trial Investigating EYLEA HD Met Its Primary Endpoint for the Treatment of Patients With Macular Edema.

BenzingaDec 18 02:16

Regeneron Says Phase 3 Trial of Higher Dose Eye Drug Eylea HD Meets Primary Target

MT NewswiresDec 17 21:01

What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals

BenzingaDec 17 21:00 · Ratings

Express News | Bayer AG - Approximately 90% of Aflibercept 8 Mg Patients Were Extended to Every 8-Week Dosing and Maintained Their Interval Through 36 Weeks

BreakingsDec 17 20:01

Express News | Regeneron Pharmaceuticals Inc - Supplementary Biologics License Application Planned for Q1 2025

BreakingsDec 17 20:00

Express News | Regeneron Pharmaceuticals Inc - Safety Data Consistent With Known Eylea Hd and Eylea Profiles

BreakingsDec 17 20:00

Express News | Eylea Hd® (Aflibercept) Injection 8 Mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision With Extended Dosing Intervals in Patients With Macular Edema Following Retinal Vein Occlusion

BreakingsDec 17 20:00

Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

Yahoo FinanceDec 17 19:53